SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

BACKGROUND: Adding bevacizumab to chemotherapy improves response rates and progression-free survival (PFS) in metastatic breast cancer (mBC). We aimed to demonstrate decreased toxicity with metronomic chemotherapy/bevacizumab compared with paclitaxel/bevacizumab. METHODS: This multicenter, randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Rochlitz, Christoph, Bigler, Martin, von Moos, Roger, Bernhard, Jürg, Matter-Walstra, Klazien, Wicki, Andreas, Zaman, Khalil, Anchisi, Sandro, Küng, Marc, Na, Kyung-Jae, Bärtschi, Daniela, Borner, Markus, Rordorf, Tamara, Rauch, Daniel, Müller, Andreas, Ruhstaller, Thomas, Vetter, Marcus, Trojan, Andreas, Hasler-Strub, Ursula, Cathomas, Richard, Winterhalder, Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057418/
https://www.ncbi.nlm.nih.gov/pubmed/27724870
http://dx.doi.org/10.1186/s12885-016-2823-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057418/
https://www.ncbi.nlm.nih.gov/pubmed/27724870
http://dx.doi.org/10.1186/s12885-016-2823-y

Ejemplares similares